(Q37961957)

26 August 2017

title

Emerging drugs in metastatic breast cancer: an update (English)

1 reference

26 August 2017

main subject

metastatic breast cancer

1 reference

2

Kadri Altundag

1 reference

26 August 2017

Cagatay Arslan

1

1 reference

26 August 2017

Omer Dizdar

series ordinal

3

1 reference

26 August 2017

language of work or name

English

0 references

publication date

28 November 2011

1 reference

Expert Opinion on Emerging Drugs

26 August 2017

published in

1 reference

26 August 2017

volume

16

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

647-667

1 reference

26 August 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Breast cancer with synchronous metastases: trends in survival during a 14-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Combining fulvestrant (Faslodex) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Preclinical investigations with epothilones in breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase I/II pharmacokinetic study of pemetrexed and epirubicin in patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Evidence-based recommendations for local therapy for soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.640672

10.1517/14728214.2011.640672

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference